Merck Serono and Pfizer are to work with the Broad Institute in Cambridge, Massachusetts to undertake genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback